Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enfortumab vedotin plus pembrolizumab vs platinum–gemcitabine chemotherapy in first-line advanced urothelial carcinoma (China phase 3)
ChiCTR2300069410Phase 3Not yet recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Feb 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of enfortumab vedotin and pembrolizumab in transitional cell carcinoma (TCC) (2 arms), sponsored by Peking University Cancer Hospital & Institute. Primary endpoints: Progression-free survival per RECIST v1.1 by blinded independent central review and Overall survival. Planned start Feb 2020; status: not yet recruiting.
02
Drugs
enfortumab vedotinpembrolizumab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on ChiCTR2300069410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069410.